Literature DB >> 28279508

Tuberculosis elimination and the challenge of latent tuberculosis.

Alberto Matteelli1, Giorgia Sulis2, Susanna Capone2, Lia D'Ambrosio3, Giovanni Battista Migliori4, Haileyesus Getahun5.   

Abstract

Latent tuberculosis infection (LTBI) affects one third to one fourth of the human population and is the reservoir for a significant proportion of emerging active tuberculosis (TB) cases, especially in low incidence countries. The World Health Organization launched in 2015 the END-TB strategy that aims at TB elimination and promotes, for the first time ever, the management of LTBI. The preventive package, basically consisting of testing and treatment for LTBI in groups at high risk of reactivation, is a mainstay of the first pillar of the strategy, alongside prompt diagnosis and early treatment of both drug-susceptible and drug-resistant TB disease. Testing and treatment for LTBI should be pursued with a programmatic perspective. This implies strong political commitment, adequate funding and an effective monitoring and evaluation system. People living with HIV and children under five years of age who are household contact of a contagious TB cases are primarily targeted in all epidemiological setting. In high resource and low incidence setting, additional at risk populations should also be the target for systematic LTBI testing and treatment. Research is urgently needed to develop diagnostic tests with higher predictive value to identify individuals that progress from infection to disease. Similarly, shorter and safer treatment regimens are needed to make the trade-off between potential benefits and harms more favourable for an increasing proportion of infected individuals.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28279508     DOI: 10.1016/j.lpm.2017.01.015

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  17 in total

1.  Vitamin D modulates human macrophage response to Mycobacterium tuberculosis DNA.

Authors:  Jorge L Cervantes; Esther Oak; John Garcia; Hongfei Liu; Paolo A Lorenzini; Deepika Batra; Arvind Chhabra; Juan C Salazar; Xavier Roca
Journal:  Tuberculosis (Edinb)       Date:  2019-05-03       Impact factor: 3.131

2.  QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results.

Authors:  Emrah Seyhoglu; Oğuz Abdullah Uyaroğlu; Abdulsamet Erden; Levent Kilic; Omer Karadag; Ali Akdogan; Sule Apras Bilgen; Ihsan Ertenli; Sedat Kiraz; Umut Kalyoncu
Journal:  Clin Rheumatol       Date:  2020-10-15       Impact factor: 2.980

Review 3.  Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria.

Authors:  Betty A Forbes; Geraldine S Hall; Melissa B Miller; Susan M Novak; Marie-Claire Rowlinson; Max Salfinger; Akos Somoskövi; David M Warshauer; Michael L Wilson
Journal:  Clin Microbiol Rev       Date:  2018-01-31       Impact factor: 26.132

4.  Notifiable infectious diseases in refugees and asylum seekers: experience from a major reception center in Munich, Germany.

Authors:  Martin Alberer; Svea Malinowski; Linda Sanftenberg; Jörg Schelling
Journal:  Infection       Date:  2018-04-03       Impact factor: 3.553

5.  Identification of protective postexposure mycobacterial vaccine antigens using an immunosuppression-based reactivation model in the zebrafish.

Authors:  Henna Myllymäki; Mirja Niskanen; Hanna Luukinen; Mataleena Parikka; Mika Rämet
Journal:  Dis Model Mech       Date:  2018-03-13       Impact factor: 5.758

6.  Diphenyleneiodonium chloride (DPIC) displays broad-spectrum bactericidal activity.

Authors:  Manitosh Pandey; Alok Kumar Singh; Ritesh Thakare; Sakshi Talwar; Pratiksha Karaulia; Arunava Dasgupta; Sidharth Chopra; Amit Kumar Pandey
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

7.  Accuracy of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Mycobacteria: a systematic review and meta-analysis.

Authors:  Yan Cao; Lei Wang; Ping Ma; Wenting Fan; Bing Gu; Shaoqing Ju
Journal:  Sci Rep       Date:  2018-03-07       Impact factor: 4.379

Review 8.  Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.

Authors:  Radha Gopalaswamy; Sivakumar Shanmugam; Rajesh Mondal; Selvakumar Subbian
Journal:  J Biomed Sci       Date:  2020-06-17       Impact factor: 8.410

9.  Improving Screening for Latent Tuberculosis Infection in a Student-run Free Clinic.

Authors:  Ambika Anand; Courtney Wagner; Steve S Kong; Elliot Griffith; Punnavit Harimtepathip; Kathryn K Baker; Stephen Rineer; Judith Simms-Cendan; Magdalena Pasarica
Journal:  Cureus       Date:  2018-04-16

10.  A significant therapeutic effect of silymarin administered alone, or in combination with chemotherapy, in experimental pulmonary tuberculosis caused by drug-sensitive or drug-resistant strains: In vitro and in vivo studies.

Authors:  Edén M Rodríguez-Flores; Dulce Mata-Espinosa; Jorge Barrios-Payan; Brenda Marquina-Castillo; Mauricio Castañón-Arreola; Rogelio Hernández-Pando
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.